Skip to content
Defeat Duchenne Canada Logo

Defeat Duchenne Canada and PPPMD Award Clinical Fellowship in Duchenne Endocrinology and Bone Fragility

June 16, 2021

Defeat Duchenne Canada and Parent Project Muscular Dystrophy Award $172,000 (CAD) Clinical Fellowship in Duchenne Endocrinology and Bone Fragility.

Award Will Sponsor a Two-Year Fellowship Under Dr. Leanne Ward, the University of Ottawa with Focus on Endocrine and Bone Complications of Duchenne.

Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), and Defeat Duchenne Canada, Canada’s leading charity fighting to defeat Duchenne, announced a collaborative research award of $172,000 (CAD) in support of a two-year Clinical Fellowship in Duchenne Endocrinology and Bone Fragility. The award will sponsor the fellowship of Dr. Kim Phung under the guidance of Dr. Leanne Ward, Professor of Pediatrics and Research Chair in Pediatric Bone Health at the University of Ottawa.

Duchenne is the most common fatal genetic disorder diagnosed in childhood, affecting approximately one in 5,000 live male births. Because people with Duchenne do not have dystrophin (a protein found in muscle), their skeletal muscles gradually become weak. A class of medications called corticosteroids (“steroids”) are used in Duchenne to slow down muscle damage and weakness.

Endocrine issues can be common in Duchenne, especially if a person is on steroids. When steroids are taken every day over a long period, they change the way the body’s natural hormones are made and work, leading to issues such as adrenal suppression, delayed puberty, and impaired growth. In addition, people with Duchenne, especially those taking steroids, have weak bones (osteoporosis), putting them at risk for fractures.

Under the guidance of Dr. Ward, the award will support Dr. Phung, currently finishing her Pediatric Endocrinology fellowship at St. Justine Hospital in Montreal, in completing a two-year fellowship in pediatric endocrine and bone diseases at the University of Ottawa, with specific focus on endocrine and bone complications of Duchenne. The Fellowship will expand research on Duchenne and its treatment-related complications, education of families and healthcare providers about the management of endocrine and bone complications, and encourage ongoing partnership to foster advocacy in these areas of care.

“The endocrinology and bone fragility effects of Duchenne and its treatment represent important clinical care issues, and are a key concern for families living with Duchenne. Defeat Duchenne Canada and PPMD are pleased to partner with each other to provide support for this important area of research as we work to educate physicians and families on common endocrine and bone issues in Duchenne, including growth, puberty, adrenal suppression, obesity and related complications, and bone fragility due to osteoporosis.”

Rachel Schrader, MS, APRN, CPNP-PC, PPMD’s Vice President of Clinical Care and Education and Nicola Worsfold HBSc, MSc, Director of Research and Advocacy at Defeat Duchenne Canada

“Dr. Phung and I are extremely excited and most grateful for the support of Defeat Duchenne Canada and PPMD. I have always admired the work of these organizations to support families. For Dr. Phung to be the beneficiary of a Fellowship position is yet another example of their empowering initiatives. I very much look forward to our ongoing work together in the areas of endocrine and bone complications of Duchenne,”

Dr. Leanne Ward, Professor of Pediatrics and Research Chair in Pediatric Bone Health at the University of Ottawa

Click on the button below to read the full press release.